Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. Many investors may have been hoping that another, larger healthcare company would acquire ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viking Therapeutics (VKTX – Research Report) and ...

Shares of Viking Therapeutics (VKTX) slid 8% post-market after the biotech company issued its Q4 earnings report and a pipeline update. Read more here.

Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.

VKTX Stock Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment Research Viking is trading at a premium to the industry, as seen in the chart below. Going by the price/book ratio, ...

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) is expected to release its earnings data after the market closes on ...